Relapsed/refractory patients

Phase II trial of selinexor plus dexamethasone in RRMM patients

Studies have shown a correlation between the expression of exportin 1 (XPO1) in the nuclear export system and with progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Smoldering Multiple Myeloma (SMM), and finally to active MM. Data from a phase I study indicated efficacy of selinexor against a number of hematologic malignancies, including MM, both alone and in combination with low-dose dexamethasone. Most of the patients in phase I trial had heavily pretreated myeloma, Non-Hodgkin Lymphoma (NHL) and, Acute Myeloid Leukemia (AML).

Dan T. Vogl, from the Division of Hematology and Oncology, University of Pennsylvania, US, and colleagues, set out to expand these findings in a study in which selinexor and low-dose dexamethasone was used to treat patients refractory to all of the most effective and currently available anti-myeloma agents. This phase II trial was published in the Journal of Clinical Oncology in January 2018.

Patients with measurable disease based on International Myeloma Working Group (IMWG) guidelines and who had been treated with at least three prior anti-myeloma regimens, including an alkylating agent, glucocorticoids, bortezomib, carfilzomib, lenalidomide, and pomalidomide were included in this study. Patients were disease-refractory to their most recent regimen, as well as refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide, either alone or in combination. This study also included a subset of patients who were disease refractory to an anti-CD38 monoclonal antibody. The primary endpoint was overall response rate (ORR).

 Study Design
  • Patients (pts) were administered 80-mg of oral selinexor, twice weekly, on days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle (six doses for 83% of the patients with quad-refractory myeloma and eight doses for 65% of the patients with penta-refractory disease), with no treatment-free intervals (TFI)
  • 20mg dexamethasone was given with each dose of selinexor
  • A 5-hydroxytryptamine-3 antagonist (ondansetron 8mg or equivalent) was given to all pts before the first dose of selinexor, 2-3 times daily, as required
 Key Findings:
  • N = 79 patients (pts); safety dataset = 78 pts; quad-refractory myeloma = 48 pts; penta-refractory myeloma = 31 pts
  • Median age = 63 years
  • Median time from diagnosis = 4 years (range <1–35)
  • Median number of prior regimens = 7 (range 3–17)
  • All pts received glucocorticoid therapy; prior alkylating agents = 97%, prior anthracyclines = 41%, autologous stem-cell transplantation (ASCT) = 77% 
  • High-risk abnormalities (which include del(17p), t(4;14) and t(14;16))  = 44% 
  • ORR = 21% (95%CI, 13–31%); pts with high-risk cytogenetic abnormalities = 35%
  • ORR for pts with quad-refractory (bortezomib, carfilzomib, lenalidomide and pomalidomide) diseases = 21%
  • ORR for pts with penta-refractory (bortezomib, carfilzomib, lenalidomide, pomalidomide and anti-CD38 antibody) diseases = 20%
  • Median duration of response = 5 months; responding pts alive at 12 months = 65%
  • Clinical benefit rate (CBR) = 33% (95%Cl, 24–44)
  • VGPR = 5% (median duration = 5 months)
  • PR = 15% (median duration = 5 months)
  • Minimal response (MR) = 13%
  • Stable disease (SD) = 35%; median duration = 2 months (0.9–7.6)
  • Progressive disease (PD) = 27%
  • Median PFS = 2.3 months
  • Median OS = 9.3 months
  • Pts who achieved ≥ a minimal response after one cycle of therapy vs stable or progressive disease: median OS = not reached vs 7.2 months, P = 0.01
  • Non-hematologic treatment-related Adverse Events (AEs):
    • Grade 3 and 4: fatigue (15%), nausea (8%), and diarrhea (5%)
    • Grade 3 hyponatremia reported in 22% of pts but reversible with supportive care
  • Hematologic AEs (grade 3 or 4):
    • Thrombocytopenia (59%), anemia (28%), neutropenia (23%) and leukopenia (15%)
    • Bleeding = 2 pts (3%), febrile neutropenia = 1 pt, infection = 14 pts
  • No differences in toxicity between pts who received 6 or 8 doses per cycle
  • Serious AEs = 22 (possibly related to study treatment = 19/22 pts)
  • Dose interruptions for AEs = 41 pts (52%), dose reductions = 29 pts (37%), and treatment discontinuation = 14 pts (18%)

This study indicated the beneficial use of combining selinexor with low-dose dexamethasone displaying an ORR of 21% in heavily pretreated MM patients who are refractory to many of the commonly used therapies. Higher response rates were associated with the use of low-dose dexamethasone, in comparison to selinexor alone. The overall survival rate was also improved when compared to historical controls. A future phase II trial is now planned, in which 122 patients with penta-refractory myeloma will be enrolled. 

  1. Vogl. D. T. et al. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. January 2018. DOI: 10.1200/JCO.2017.75.5207